JP7840319B2 - Ｇｌｐ－１受容体アゴニスト融合物をコードするウイルスベクター及び代謝性疾患の治療におけるその使用 - Google Patents

Ｇｌｐ－１受容体アゴニスト融合物をコードするウイルスベクター及び代謝性疾患の治療におけるその使用

Info

Publication number
JP7840319B2
JP7840319B2 JP2023513298A JP2023513298A JP7840319B2 JP 7840319 B2 JP7840319 B2 JP 7840319B2 JP 2023513298 A JP2023513298 A JP 2023513298A JP 2023513298 A JP2023513298 A JP 2023513298A JP 7840319 B2 JP7840319 B2 JP 7840319B2
Authority
JP
Japan
Prior art keywords
sequence
aav
glp
seq
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023513298A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022046815A5 (https=
JP2023543125A (ja
JP2023543125A5 (https=
Inventor
ウイルソン，ジェームス・エム
ヒンデラー，クリスチャン
真 堀内
Original Assignee
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア filed Critical ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア
Publication of JP2023543125A publication Critical patent/JP2023543125A/ja
Publication of JPWO2022046815A5 publication Critical patent/JPWO2022046815A5/ja
Publication of JP2023543125A5 publication Critical patent/JP2023543125A5/ja
Application granted granted Critical
Publication of JP7840319B2 publication Critical patent/JP7840319B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2023513298A 2020-08-24 2021-08-24 Ｇｌｐ－１受容体アゴニスト融合物をコードするウイルスベクター及び代謝性疾患の治療におけるその使用 Active JP7840319B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063069500P 2020-08-24 2020-08-24
US63/069,500 2020-08-24
PCT/US2021/047411 WO2022046815A1 (en) 2020-08-24 2021-08-24 Viral vectors encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases

Publications (4)

Publication Number Publication Date
JP2023543125A JP2023543125A (ja) 2023-10-13
JPWO2022046815A5 JPWO2022046815A5 (https=) 2024-09-02
JP2023543125A5 JP2023543125A5 (https=) 2024-09-02
JP7840319B2 true JP7840319B2 (ja) 2026-04-03

Family

ID=78032497

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513298A Active JP7840319B2 (ja) 2020-08-24 2021-08-24 Ｇｌｐ－１受容体アゴニスト融合物をコードするウイルスベクター及び代謝性疾患の治療におけるその使用

Country Status (9)

Country Link
US (1) US20230372539A1 (https=)
EP (1) EP4200429A1 (https=)
JP (1) JP7840319B2 (https=)
CN (1) CN116438312A (https=)
AU (1) AU2021332235A1 (https=)
BR (1) BR112023003310A2 (https=)
CA (1) CA3190399A1 (https=)
MX (1) MX2023002293A (https=)
WO (1) WO2022046815A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL315256A (en) * 2022-03-03 2024-10-01 Univ Pennsylvania AAV vectors for delivery of GLP-1 receptor agonist fusions
GB202403805D0 (en) * 2024-03-15 2024-05-01 Ucl Business Ltd Compositions and methods of treatment
CN119351440B (zh) * 2024-12-25 2025-04-25 浙江大学衢州研究院 表达glp-1的重组载体、重组酵母及应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104327187A (zh) 2014-10-11 2015-02-04 上海兴迪金生物技术有限公司 一种重组人GLP-1-Fc融合蛋白
JP2018523477A (ja) 2015-08-06 2018-08-23 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Ｇｌｐ−１及び代謝性疾患を治療するための組成物におけるその使用
WO2020063628A1 (zh) 2018-09-26 2020-04-02 北京辅仁瑞辉生物医药研究院有限公司 GLP1-Fc融合蛋白及其缀合物
JP2020509761A (ja) 2017-03-14 2020-04-02 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 免疫グロブリンのＦｃ部分を含む二重標的融合タンパク質

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US6268213B1 (en) 1992-06-03 2001-07-31 Richard Jude Samulski Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5869305A (en) 1992-12-04 1999-02-09 The University Of Pittsburgh Recombinant viral vector system
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
WO1998046728A1 (en) 1997-04-14 1998-10-22 Cell Genesys, Inc. Methods for increasing the efficiency of recombinant aav product
WO1999061643A1 (en) 1998-05-27 1999-12-02 University Of Florida Method of preparing recombinant adeno-associated virus compositions by using an iodixananol gradient
ES2340230T3 (es) 1998-11-10 2010-05-31 University Of North Carolina At Chapel Hill Vectores viricos y sus procedimientos de preparacion y administracion.
PT1916258E (pt) 1999-08-09 2014-07-29 Genzyme Corp Aumento da expressão de uma sequência nucleotídica heteróloga de cadeia simples a partir de vectores virais recombinantes por concepção da sequência de maneira que esta forme pares de bases intracadeia
US7201898B2 (en) 2000-06-01 2007-04-10 The University Of North Carolina At Chapel Hill Methods and compounds for controlled release of recombinant parvovirus vectors
NZ532635A (en) 2001-11-13 2007-05-31 Univ Pennsylvania A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
AU2003274397A1 (en) 2002-06-05 2003-12-22 University Of Florida Production of pseudotyped recombinant aav virions
MXPA05013565A (es) 2003-06-12 2006-03-09 Lilly Co Eli Proteinas de fusion analogas al glp-1.
CN1856576B (zh) 2003-09-30 2011-05-04 宾夕法尼亚州立大学托管会 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
WO2006110689A2 (en) 2005-04-07 2006-10-19 The Trustees Of The University Of Pennsylvania Method of increasing the function of an aav vector
EP1777906A1 (en) 2005-06-09 2007-04-25 Matsushita Electric Industrial Co., Ltd. Amplitude error compensating apparatus and orthogonality error compensating apparatus
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
US20130023033A1 (en) 2010-03-29 2013-01-24 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
FR2977562B1 (fr) 2011-07-06 2016-12-23 Gaztransport Et Technigaz Cuve etanche et thermiquement isolante integree dans une structure porteuse
US9719106B2 (en) 2013-04-29 2017-08-01 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
JP7455579B2 (ja) 2017-02-28 2024-03-26 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 新規アデノ随伴ウイルス（ａａｖ）クレードｆベクター及びその用途
AU2019340472A1 (en) * 2018-09-12 2021-04-01 Quiapeg Pharmaceuticals Ab Releasable GLP-1 conjugates
WO2020184941A1 (en) * 2019-03-08 2020-09-17 Genexine, Inc. Glp-1 fusion proteins and uses thereof
PE20220014A1 (es) 2019-04-29 2022-01-11 Univ Pennsylvania Nuevas capsides de aav y composiciones que las contienen
WO2021081217A1 (en) * 2019-10-23 2021-04-29 The Trustees Of The University Of Pennsylvania Compositions for drg-specific reduction of transgene expression

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104327187A (zh) 2014-10-11 2015-02-04 上海兴迪金生物技术有限公司 一种重组人GLP-1-Fc融合蛋白
JP2018523477A (ja) 2015-08-06 2018-08-23 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Ｇｌｐ−１及び代謝性疾患を治療するための組成物におけるその使用
JP2020509761A (ja) 2017-03-14 2020-04-02 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 免疫グロブリンのＦｃ部分を含む二重標的融合タンパク質
WO2020063628A1 (zh) 2018-09-26 2020-04-02 北京辅仁瑞辉生物医药研究院有限公司 GLP1-Fc融合蛋白及其缀合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NAMBIAR K. et al.，Transduction evaluation of novel AAV natural isolates in nonhuman primates using a barcoded transgene system，ESGCT 27th Annual Congress In collaboration with SETGyc Barcelona, Spain，2019年，POSTER PRESENTATIONS, A19, 「P002」
RIVERA VM. et al.，Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer，Blood，2005年，vol. 105, no. 4，pp. 1424-1430

Also Published As

Publication number Publication date
MX2023002293A (es) 2023-05-19
EP4200429A1 (en) 2023-06-28
CN116438312A (zh) 2023-07-14
AU2021332235A1 (en) 2023-03-23
WO2022046815A1 (en) 2022-03-03
BR112023003310A2 (pt) 2023-05-02
CA3190399A1 (en) 2022-03-03
US20230372539A1 (en) 2023-11-23
JP2023543125A (ja) 2023-10-13
WO2022046815A9 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
US12221615B2 (en) GLP-1 and use thereof in compositions for treating metabolic diseases
JP7840319B2 (ja) Ｇｌｐ－１受容体アゴニスト融合物をコードするウイルスベクター及び代謝性疾患の治療におけるその使用
US20230405150A1 (en) Viral vector encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases in felines
US20250171515A1 (en) Aav vectors for delivery of glp-1 receptor agonist fusions
US20250388926A1 (en) Viral vector genome encoding an insulin fusion protein
US20250186613A1 (en) Viral vectors encoding glp-2 receptor agonist fusions and uses thereof in treating short bowel syndrome
US20250186612A1 (en) Viral vectors encoding parathyroid hormone fusions and uses thereof in treating hypoparathyroidism

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240823

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240823

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250723

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260225

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260324

R150 Certificate of patent or registration of utility model

Ref document number: 7840319

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150